ENTO Valuation

Entero Therapeutics Inc

Add to Watchlist

Advanced Chart

3.900

+0.44(12.717%)1D

ENTO Relative Valuation

ENTO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENTO is overvalued; if below, it's undervalued.

Historical Valuation

Entero Therapeutics Inc (ENTO) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.43. The fair price of Entero Therapeutics Inc (ENTO) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.90

Fair

-0.97

Trailing

Forward

0.00

EV/EBITDA

Entero Therapeutics Inc. (ENTO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-2.17

EV/EBIT

Entero Therapeutics Inc. (ENTO) has a current EV/EBIT of -2.17. The 5-year average EV/EBIT is -1.01. The thresholds are as follows: Strongly Undervalued below -2.86, Undervalued between -2.86 and -1.94, Fairly Valued between -0.09 and -1.94, Overvalued between -0.09 and 0.84, and Strongly Overvalued above 0.84. The current Forward EV/EBIT of -2.17 falls within the Undervalued range.

4.43

Entero Therapeutics Inc. (ENTO) has a current PS of 4.43. The 5-year average PS is 0.09. The thresholds are as follows: Strongly Undervalued below -0.77, Undervalued between -0.77 and -0.34, Fairly Valued between 0.52 and -0.34, Overvalued between 0.52 and 0.96, and Strongly Overvalued above 0.96. The current Forward PS of 4.43 falls within the Strongly Overvalued range.

0.00

P/OCF

Entero Therapeutics Inc. (ENTO) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.23. The thresholds are as follows: Strongly Undervalued below -1.64, Undervalued between -1.64 and -0.94, Fairly Valued between 0.48 and -0.94, Overvalued between 0.48 and 1.19, and Strongly Overvalued above 1.19. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.10

P/FCF

Entero Therapeutics Inc. (ENTO) has a current P/FCF of 0.10. The 5-year average P/FCF is -0.18. The thresholds are as follows: Strongly Undervalued below -1.81, Undervalued between -1.81 and -0.99, Fairly Valued between 0.64 and -0.99, Overvalued between 0.64 and 1.46, and Strongly Overvalued above 1.46. The current Forward P/FCF of 0.10 falls within the Historic Trend Line -Fairly Valued range.

Entero Therapeutics Inc (ENTO) has a current Price-to-Book (P/B) ratio of -0.87. Compared to its 3-year average P/B ratio of 0.69 , the current P/B ratio is approximately -227.21% higher. Relative to its 5-year average P/B ratio of 0.38, the current P/B ratio is about -331.57% higher. Entero Therapeutics Inc (ENTO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -420.86%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -346.42% , the current FCF yield is about -100.00% lower.

-0.87

P/B

Median3y

0.69

Median5y

0.38

0.00

FCF Yield

Median3y

-420.86

Median5y

-346.42

Competitors Valuation Multiple

The average P/S ratio for ENTO's competitors is 1.34, providing a benchmark for relative valuation. Entero Therapeutics Inc Corp (ENTO) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ENTO.O

Entero Therapeutics Inc

Ensysce Biosciences Inc

Alaunos Therapeutics Inc

SRx Health Solutions Inc

0.23

0.66%

5.70M

Performance Decomposition

Market capitalization of ENTO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ENTO in the past 1 year is driven by Unknown.